NCT00329810
Completed
Phase 4
A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients
Overview
- Phase
- Phase 4
- Intervention
- Aripiprazole
- Conditions
- Schizophrenia
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Enrollment
- 500
- Primary Endpoint
- Clinical Global Impression scale at endpoint
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of Schizophrenia
- •score of 2-6 in the CGI-S scale at basline
- •ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment
Exclusion Criteria
- •women of child bearing potential
- •women pregnant or breast feeding
- •patients with a score of 0,-1 or 7
- •substance use
Arms & Interventions
Switch
Intervention: Aripiprazole
Outcomes
Primary Outcomes
Clinical Global Impression scale at endpoint
Secondary Outcomes
- Change in Clinical Global Impression scale and cognition scales at endpoint
Similar Trials
Completed
Not Applicable
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar DisorderSchizophreniaBipolar DisorderNCT00216723Korea Otsuka Pharmaceutical Co., Ltd.3,000
Completed
Phase 1
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleSchizophreniaNCT01552772Otsuka Pharmaceutical Development & Commercialization, Inc.60
Completed
Phase 4
Trial of Aripiprazole in the Treatment of CD in AdolescentsConduct DisorderNCT00250705University of Iowa12
Terminated
Phase 4
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in SchizophreniaSchizophreniaNCT00712270Kettering Health Network21
Completed
Phase 4
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18